FDA Approves Biocon Biologics’ Biosimilar YESINTEK: What You Need to Know

The U.S. Food and Drug Administration (FDA) has approved Biocon Biologics’ YESINTEK™ (ustekinumab-kfce), a biosimilar to Stelara® (ustekinumab). YESINTEK™ is authorized for treating Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. ✏️▫️Clinical trials have demonstrated that YESINTEK™ is equivalent to Stelara® in terms of efficacy, safety, immunogenicity, and pharmacokinetics. A phase 3 randomized, double-blind, … Read more

Novo Nordisk’s $1.2 Billion Investment in Denmark Explained

🔹Novo Nordisk has announced a major investment of DKr8.5bn ($1.2bn) to establish a new production facility in Odense, Denmark. The facility, unveiled on December 16, will focus on manufacturing therapies for rare diseases, including treatments for haemophilia. 🔹The site will also feature a warehouse spanning over 40,000m². This development is expected to enhance Novo Nordisk’s … Read more

USFDA Approves Granules Pharmaceuticals’ Generic Vyvanse Chewables

Granules Pharmaceuticals, Inc. has successfully received USFDA approval for its bioequivalent generic version of Lisdexamfetamine Dimesylate Chewable Tablets in various strengths: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg. This generic version corresponds to Vyvanse® Chewable Tablets by Takeda Pharmaceuticals USA Inc. Approved Indications: Approval achieved in the first review … Read more

How Science Revolutionized Medicine💊 and Healthcare🏥

The essay captures the transformative impact of science on various aspects of human life, emphasizing its pivotal role in shaping modern civilization. Here’s a brief analysis: The piece effectively conveys how science drives innovation and addresses global challenges while urging mindful stewardship of its power. It’s an inspiring reminder of science’s potential to shape a … Read more

MHRA Extends Licence for Blincyto: What It Means for ALL Patients🪪

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for Amgen’s Blincyto (blinatumomab), expanding its use in acute lymphoblastic leukaemia (ALL). This immunotherapy is now approved for adults with Philadelphia chromosome-negative (Ph-) CD19-positive B-cell precursor ALL during the consolidation phase of frontline treatment. This phase aims to eliminate any remaining leukaemia … Read more

Cipla has launched India’s first inhalable insulin

🔷Cipla has launched India’s first inhalable insulin, Afrezza, after receiving approval from the Central Drugs Standard Control Organisation (CDSCO). 🔷Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management. 🔷This breakthrough product aims to improve glycemic control for adults with both type 1 and type 2 diabetes who … Read more

The Role of the Tumor Microenvironment in Immune Checkpoint Pathways

The tumor microenvironment (TME) is indeed a critical determinant of cancer progression and immune evasion. Its dynamic and immunosuppressive nature allows tumors to adapt and thrive in hostile conditions, making it a key focus for developing novel therapeutic strategies. Key Mechanisms of TME Reprogramming: Therapeutic Opportunities: Understanding the interplay between the TME and immune system … Read more

Inhibition of Cell Apoptosis Signals and Immune Evasion

♦️Cancer cells use complex mechanisms to evade immune surveillance, with inhibition of apoptotic signaling being a key strategy. Apoptosis, or programmed cell death, is an important process of self-destruction of damaged or dysfunctional cells that prevents malignancy and maintains tissue homeostasis. In cancer, this pathway is often disrupted, allowing tumor cells to survive and proliferate … Read more

Innovations in Media Fill Testing: What the Pharmaceutical Industry Needs to Know

The advancements in pharmaceutical manufacturing technologies, particularly in media fill testing, represent a significant leap forward in ensuring the quality and sterility of products. Here’s a breakdown of the key developments mentioned: These technologies collectively enable pharmaceutical companies to perform media fill tests with greater precision, reliability, and speed. By leveraging these innovations, companies not … Read more

Global Orally Disintegrating Tablet (ODT) Market is expected to exceed more than US$ 26.50 Bn by 2025 at a CAGR of 11.5% in the given forecast period

Global Orally Disintegrating Tablet Market Overview: An Orally Disintegrating Tablet is a drug dosage form available for a limited range of over-the-counter and prescription medications. It differs from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. ODTs dissolve or disintegrate in the mouth without water within … Read more

Exit mobile version